Replimune's Biologics License Application for Advanced Cutaneous Melanoma Drug Rejected by FDA

MT Newswires Live04-11 00:00

Replimune Group's (REPL) biologics license application for vusolimogene oderparepvec was rejected by the US Food and Drug Administration, the regulator said in a complete response letter on Friday.

The application was for vusolimogene oderparepvec plus nivolumab to treat adults with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 blocking antibody-based therapy, the letter said.

The regulator and experts unanimously decided that the data presented in the application were "insufficient" to show that the treatment is effective for advanced melanoma, the letter added.

Shares of Replimune Group were down 19.5% before being halted on Nasdaq at about 11:02 a.m. ET.

Price: 4.76, Change: -1.15, Percent Change: -19.46

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626118741?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-11 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626118741","market":"fut","top_or_hot":-1,"title":"Replimune's Biologics License Application for Advanced Cutaneous Melanoma Drug Rejected by FDA","media":"MT Newswires Live","content":"<html><body><p> Replimune Group's (REPL) biologics license application for vusolimogene oderparepvec was rejected by the US Food and Drug Administration, the regulator said in a complete response letter on Friday.</p><p>The application was for vusolimogene oderparepvec plus nivolumab to treat adults with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 blocking antibody-based therapy, the letter said.</p><p>The regulator and experts unanimously decided that the data presented in the application were \"insufficient\" to show that the treatment is effective for advanced melanoma, the letter added.</p><p>Shares of Replimune Group were down 19.5% before being halted on Nasdaq at about 11:02 a.m. ET.</p><p>Price: 4.76, Change: -1.15, Percent Change: -19.46</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Replimune's Biologics License Application for Advanced Cutaneous Melanoma Drug Rejected by FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReplimune's Biologics License Application for Advanced Cutaneous Melanoma Drug Rejected by FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-11 00:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Replimune Group's (REPL) biologics license application for vusolimogene oderparepvec was rejected by the US Food and Drug Administration, the regulator said in a complete response letter on Friday.</p><p>The application was for vusolimogene oderparepvec plus nivolumab to treat adults with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 blocking antibody-based therapy, the letter said.</p><p>The regulator and experts unanimously decided that the data presented in the application were \"insufficient\" to show that the treatment is effective for advanced melanoma, the letter added.</p><p>Shares of Replimune Group were down 19.5% before being halted on Nasdaq at about 11:02 a.m. ET.</p><p>Price: 4.76, Change: -1.15, Percent Change: -19.46</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2626118741","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626118741","pubTimestamp":1775836857,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Replimune Group's  biologics license application for vusolimogene oderparepvec was rejected by the US Food and Drug Administration, the regulator said in a complete response letter on Friday.The application was for vusolimogene oderparepvec plus nivolumab to treat adults with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 blocking antibody-based therapy, the letter said.The regulator and experts unanimously decided that the data presented in the application were \"insufficient\" to show that the treatment is effective for advanced melanoma, the letter added.Shares of Replimune Group were down 19.5% before being halted on Nasdaq at about 11:02 a.m. ET.Price: 4.76, Change: -1.15, Percent Change: -19.46","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","REPL":"Replimune Group Inc.","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","AEIS":"先进能源工业公司","BK4157":"电子设备和仪器","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BK4588":"碎股","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","LABU":"三倍做多标普生物-Direxion"},"translate_title":"Replimune晚期皮肤黑色素瘤药物生物制品许可申请被FDA拒绝","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEIS":1.5,"LABU":1.5,"REPL":1},"content_text":"Replimune Group's (REPL) biologics license application for vusolimogene oderparepvec was rejected by the US Food and Drug Administration, the regulator said in a complete response letter on Friday.The application was for vusolimogene oderparepvec plus nivolumab to treat adults with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 blocking antibody-based therapy, the letter said.The regulator and experts unanimously decided that the data presented in the application were \"insufficient\" to show that the treatment is effective for advanced melanoma, the letter added.Shares of Replimune Group were down 19.5% before being halted on Nasdaq at about 11:02 a.m. ET.Price: 4.76, Change: -1.15, Percent Change: -19.46","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626118741","isCrawlerRequest":true}